SCHEMBL3792536

SCHEMBL3792536

Clc1cc(Cl)nc(-c2cc3ccccc3o2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 1/20 0.48
▸ MAPT P10636 4/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ MAOB P27338 4/20 0.47
▸ MAOA P21397 3/20 0.47
▸ ADRA2A P08913 2/20 0.46
▸ METAP2 P50579 1/20 0.46
▸ CYP19A1 P11511 1/20 0.45
▸ HPGD P15428 4/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ GRM4 Q14833 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ ADRA2B P18089 1/20 0.45
▸ ADRA2C P18825 1/20 0.45
▸ NISCH Q9Y2I1 1/20 0.45
▸ ALOX5 P09917 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30561833 0.86 MAOB (0.55) MAPTNPC1RAB9AMAOBMAOA
SCHEMBL21476452 0.78 MAOB (0.53) MAPTNPC1RAB9AMAOBMAOA
SCHEMBL20576364 0.77 NPC1 (0.51) MKNK1MAPTNPC1RAB9AMAOB
SCHEMBL30036439 0.77 MAOB (0.63) MAPTNPC1RAB9AMAOBMAOA
SCHEMBL103158 0.77 MAOB (0.63) MAPTNPC1RAB9AMAOBMAOA
SCHEMBL4510137 0.77 METAP1 (0.48) MKNK1MAPTNPC1RAB9AMAOB
SCHEMBL17687570 0.77 CYP19A1 (0.64) MKNK1MAPTNPC1RAB9AMAOB
SCHEMBL21476768 0.76 MAOB (0.51) MAPTNPC1RAB9AMAOBMAOA
SCHEMBL30834585 0.76 ADRA2A (0.45) MKNK1MAPTNPC1RAB9AMAOB
SCHEMBL30477739 0.76 MAOB (0.46) MAPTNPC1RAB9AMAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2166849-A1 SUBSTITUTED PYRAZOLE COMPOUNDS Miikana Therapeutics, Inc. (US) 2010-03-31 — — EP disclosed
US-20090029992-A1 SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. 2009-01-29 — — US disclosed
US-20090029992-A1 SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. 2009-01-29 — — US disclosed
US-20090029992-A1 SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. 2009-01-29 — — US disclosed
WO-2008154026-A1 SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. (US) 2008-12-18 — — WO disclosed
WO-2008154026-A1 SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. (US) 2008-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029992-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AURKC, AURKA, AURKB MKNK1 54/4885MAPT 1396/4885NPC1 1369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback